Morphosys Ag

Pfizer Corporation

Gpc Biotech Ag

Universitaetsklinikum Tuebingen

Michael Tesar

Ute Jäger

Kathrin Ladetzki-Baehs

Bianca Ahrens

Sangita M Baxi

Richard Michael Jerome

Leslie Lynne Sharp

Libbey Anne Yates

Ute Jaeger

Robert Rauchenberger

Vinay Radhakrishnan

Timothy Scott Fisher

Theodore Lawrence Oliphant

Moritz Zulley

Elisabeth Thomassen-Wolf

Alexandra Kraus

Zoltan Nagy

Andreas Paul Peschel

Christoph Michael Ernst

Christoph Brunner

Mark William Elliott

Regis Doyonnas

Ute JÄGER

Heather Laurence Jones

Cris Kamperschroer

Adekunle Olatunbosun Onadipe

Kristin Elizabeth Thomas

Victoria Alexandria Love

Simon Paul Bergqvist

Daisy Marie Ziegemeier

Allison Karlyn Rohner

The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

Generation and profiling of fully human HuCAL gold-derived therapeutic antibodies specific for human CD38

Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38

The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.

4-1BB binding molecules

This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.

Anti-staphylococcal antibodies

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.

Anti-CD38 human antibodies and uses thereof

Method of producing 4-1BB binding molecules and associated nucleic acids

The present invention provides methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

Generation and profiling of fully human HuCAL gold&#xae;-derived therapeutic antibodies specific for human CD3i

The present invention nucleic acids encoding novel antibodies and functional fragments thereof specific for CD38. Such antibodies are useful for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.

Fully human therapeutic antibodies specific for human CD38

The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.

Generation and Profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38

The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods for using the same. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.

Generation and profiling of fully human gold-derived therapeutic antibodies specific for human CD38

The present invention relates to polypeptide compositions which bind to cell surface epitopes and, in multivalent forms, cause or lead to the killing of cells including lymphoid tumor cells, and in the case of monovalent forms, cause immunosuppression or otherwise inhibit activation of lymphocytes. The invention further relates to nucleic acids encoding the polypeptides, methods for the production of the polypeptides, methods for killing cells, methods for immunosuppressing a patient, pharmaceutical, diagnostic and multivalent compositions and kits comprising the polypeptides and uses of the polypeptides.

Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells

Growing community of inventors

Friedberg, Germany

Michael Tesar